![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS Number:0074B Cambridge Antibody Tech Group PLC 17 November 1999 For Further Information Contact: Cambridge Antibody Technology Group plc Dr John Aston, Finance Director Tel: +44 (0) 1763 263233 Rowena Gardner, Communications Manager HCC.De Facto City/Financial, Sue Charles/Rebecca Hennessy Tel: +44 (0) 171 496 3300 Trade/Science, Nikul Odedra NEW DATA FROM CLINICAL TRIALS WITH D2E7 FOR RHEUMATOID ARTHRITIS New data from clinical trials conducted by BASF Pharma with the development compound D2E7 for the long-term treatment of rheumatoid arthritis (RA) are being presented today at the 63rd Annual Scientific Meeting of the American College of Rheumatology meeting in Boston, MA. D2E7, a fully human antibody, belongs to a new class of medicines that neutralises TNF-alpha. A randomised, double-blind placebo-controlled study with 283 patients found that D2E7 when given by self injection at a dose of 20 to 80 mg once weekly over a three-month period was significantly superior to placebo. A separate study examined radiographic disease progression among 66 patients with long-term RA via X-rays. Results suggest that D2E7 slows disease progression in RA patients. D2E7 was initially isolated and optimised as part of a research collaboration between BASF Pharma and Cambridge Antibody Technology (CAT). BASF Pharma is solely responsible for the pre-clinical/clinical development and marketing of D2E7. BASF Pharma is planning to initiate Phase III clinical trials with D2E7 in the near future. Notes to editors: 1. TNF is a cell communication protein that plays a role in the immune system. In RA, TNF accumulates disproportionately in the joints and initiates an inflammatory response that causes swelling, pain and joint damage - primarily in the hands, feet, elbows and knees, and often rendering the patient unable to perform daily activities. Anti-TNF drugs neutralise this reaction by blocking the chemical message sent from cell to cell that results in joint inflammation and swelling. Essentially, D2E7 is designed to capture TNF and to interrupt the process that can lead to the symptoms of RA. 2. Placebo: An inactive substance administered to some patients in a clinical trial, instead of the drug under investigation. 3. Double blind: A type of clinical trial in which neither the doctor or the patient knows whether the patient is being administered a placebo or the test drug. 4. BASF Pharma represents the global corporate pharmaceutical operations of BASF Aktiengesellschaft with Knoll AG, Germany at its centre. In 1998, BASF Pharma sales amounted to DM 4.51 billion, representing an increase of 10 per cent over the preceding year. BASF Pharma has a global workforce of more than 13,000. 5. Knoll Pharmaceutical Company, headquartered in Mount Olive, NJ, is the US pharmaceutical unit of BASF Corporation and part of BASF Pharma, the global pharmaceutical business of BASF, AG. 6. Cambridge Antibody Technology (LSE: CAT) is a UK biotechnology company using its proprietary technologies in fully human monoclonal antibodies for drug discovery and drug development. Based in Melbourn, 10 miles south of Cambridge, England, CAT currently employs around 150 people. In March 1997, CAT completed its initial public offering and listing on the London Stock Exchange, raising approximately #41 million. CAT has a world-leading platform technology for rapidly isolating fully human monoclonal antibodies using phage display systems. CAT has an extensive phage display antibody library, currently incorporating around 100 billion distinct antibodies. This library forms the basis for the company's strategy to develop a portfolio of clinical development programmes and for discovering new drug leads using functional genomics. Three fully human therapeutic antibodies developed by CAT are at various stages of clinical trials. CAT has a number of license and collaborative agreements in place with pharmaceutical and biotechnology companies including: Eli Lilly, Pfizer, BASF Pharma, Genentech, ICOS Corporation, Genetics Institute/BASF Pharma, Wyeth-Ayerst, Human Genome Sciences and AstraZeneca. END MSCBSBBBLXBCCCR
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions